Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could fewer chemo rounds plus a targeted drug beat standard care for older lymphoma patients?

NCT ID NCT07215585

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether older or frail adults newly diagnosed with large B-cell lymphoma can get just 2 rounds of chemo (R-mini-CHOP) followed by a new drug called AZD0486, instead of the usual 6 rounds of chemo. The goal is to see if the shorter chemo-plus-new-drug approach works better and is safer. About 420 participants will be randomly assigned to one of the two treatment plans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 420 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jul 2033

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 130 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Participants are either 80 years of age or older, OR 65 to 79 years of age or older and classified as unfit per sGA, and otherwise not considered candidates for full-dose R-CHOP per investigator assessment; * Histologically confirmed diagnosis of previously untreated LBCL as per WHO-HEM5 (excluding plasmablastic lymphoma) and follicular large cell lymphoma; * FDG-avid and measurable disease as per Lugano and Ann Arbor staging; * Stage I bulky (7.5 cm and greater) to Stage IV; * ECOG performance status 0 to 2; * Adequate bone marrow, liver, renal and cardiac function. The above is a summary, other inclusion criteria details may apply. * As judged by the investigator, any evidence of diseases which make it undesirable for the participant to participate in the study, or that would jeopardise compliance with the protocol * Diagnosis of post-transplant lymphoproliferative disease, plasmablastic lymphoma, Richter's transformation, prior history of or concurrent indolent lymphoma (including de novo transformed or composite lymphoma). * History of CNS involvement by their B-NHL or history of clinically relevant CNS medical condition * Known history of hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). * Active or uncontrolled infection * Major cardiac abnormalities * Prior anti-lymphoma therapy except for corticosteroids for symptom control * Requires chronic immunosuppressive therapy for active autoimmune/inflammatory condition, with some exceptions The above is a summary, other exclusion criteria details may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Large B-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Large B-cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    64 sites in 11 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    NOT_YET_RECRUITING

    Clayton, 3168, Australia

  • Research Site

    WITHDRAWN

    Macquarie University, 2109, Australia

  • Research Site

    RECRUITING

    Melbourne, 3000, Australia

  • Research Site

    NOT_YET_RECRUITING

    Nedlands, 6009, Australia

  • Research Site

    NOT_YET_RECRUITING

    Waratah, 2298, Australia

  • Research Site

    WITHDRAWN

    Antwerp, 2030, Belgium

  • Research Site

    NOT_YET_RECRUITING

    Brussels, 1200, Belgium

  • Research Site

    RECRUITING

    Ghent, 9000, Belgium

  • Research Site

    RECRUITING

    Leuven, 3000, Belgium

  • Research Site

    SUSPENDED

    Roeselare, 8800, Belgium

  • Research Site

    RECRUITING

    Yvoir, 5530, Belgium

  • Research Site

    RECRUITING

    Porto Alegre, 90035-003, Brazil

  • Research Site

    RECRUITING

    São Paulo, 05652000, Brazil

  • Research Site

    RECRUITING

    Calgary, Alberta, T2N 5G2, Canada

  • Research Site

    NOT_YET_RECRUITING

    Victoria, British Columbia, V8R 6V5, Canada

  • Research Site

    NOT_YET_RECRUITING

    Hamilton, Ontario, L8V 5C2, Canada

  • Research Site

    RECRUITING

    Ottawa, Ontario, K1H 8L6, Canada

  • Research Site

    RECRUITING

    Beijing, 100730, China

  • Research Site

    RECRUITING

    Changchun, 130021, China

  • Research Site

    RECRUITING

    Chengdu, 610041, China

  • Research Site

    NOT_YET_RECRUITING

    Chongqing, 400042, China

  • Research Site

    NOT_YET_RECRUITING

    Fuzhou, 350011, China

  • Research Site

    RECRUITING

    Guangzhou, 510060, China

  • Research Site

    NOT_YET_RECRUITING

    Guangzhou, 510280, China

  • Research Site

    NOT_YET_RECRUITING

    Haikou, 570311, China

  • Research Site

    NOT_YET_RECRUITING

    Hefei, 230012, China

  • Research Site

    RECRUITING

    Jinan, 250117, China

  • Research Site

    NOT_YET_RECRUITING

    Kunming, 650101, China

  • Research Site

    NOT_YET_RECRUITING

    Nanchang, 330000, China

  • Research Site

    NOT_YET_RECRUITING

    Nanning, 530021, China

  • Research Site

    WITHDRAWN

    Nantong, 226001, China

  • Research Site

    RECRUITING

    Shanghai, 200003, China

  • Research Site

    RECRUITING

    Shanghai, 20032, China

  • Research Site

    NOT_YET_RECRUITING

    Wuhan, 430030, China

  • Research Site

    NOT_YET_RECRUITING

    Xiamen, 361003, China

  • Research Site

    RECRUITING

    Hong Kong, 999077, Hong Kong

  • Research Site

    NOT_YET_RECRUITING

    Lai Chi Kok, Hong Kong

  • Research Site

    WITHDRAWN

    Shatin, 00000, Hong Kong

  • Research Site

    NOT_YET_RECRUITING

    Akashi, 673-8558, Japan

  • Research Site

    RECRUITING

    Bunkyō City, 113-8677, Japan

  • Research Site

    NOT_YET_RECRUITING

    Himeji-shi, 670-8540, Japan

  • Research Site

    RECRUITING

    Kōtoku, 135-8550, Japan

  • Research Site

    NOT_YET_RECRUITING

    Kumamoto, 860-8556, Japan

  • Research Site

    NOT_YET_RECRUITING

    Matsumoto-shi, 399-8701, Japan

  • Research Site

    NOT_YET_RECRUITING

    Matsuyama, 791-0280, Japan

  • Research Site

    NOT_YET_RECRUITING

    Meguro-ku, 152-8902, Japan

  • Research Site

    NOT_YET_RECRUITING

    Nagoya, 460-0001, Japan

  • Research Site

    NOT_YET_RECRUITING

    Okayama, 701-1192, Japan

  • Research Site

    NOT_YET_RECRUITING

    Osaka, 543-8555, Japan

  • Research Site

    RECRUITING

    Osaka, 545-8586, Japan

  • Research Site

    NOT_YET_RECRUITING

    Otaki-Shi, 739-0696, Japan

  • Research Site

    NOT_YET_RECRUITING

    Sapporo, 003-0804, Japan

  • Research Site

    NOT_YET_RECRUITING

    Sunto-gun, 411-8777, Japan

  • Research Site

    RECRUITING

    Yamagata, 990-9585, Japan

  • Research Site

    RECRUITING

    Yokohama, 241-8515, Japan

  • Research Site

    NOT_YET_RECRUITING

    Kielce, 25-734, Poland

  • Research Site

    RECRUITING

    Krakow, 30-727, Poland

  • Research Site

    NOT_YET_RECRUITING

    Lodz, 93-513, Poland

  • Research Site

    NOT_YET_RECRUITING

    Lublin, 20-090, Poland

  • Research Site

    NOT_YET_RECRUITING

    Wroclaw, 50-367, Poland

  • Research Site

    RECRUITING

    Seoul, 03080, South Korea

  • Research Site

    RECRUITING

    Seoul, 5505, South Korea

  • Research Site

    RECRUITING

    Ankara, 06620, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Antalya, 07025, Turkey (Türkiye)

  • Research Site

    NOT_YET_RECRUITING

    Glasgow, Scotland, G12 0YN, United Kingdom

  • Research Site

    RECRUITING

    London, NW1 2PG, United Kingdom

  • Research Site

    RECRUITING

    Newcastle upon Tyne, NE7 7AF, United Kingdom

  • Research Site

    NOT_YET_RECRUITING

    Nottingham, NG5 1PB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.